170 results
Page 8 of 9
8-K
EX-99.1
jnvft1e
15 May 19
Results of Operations and Financial Condition
9:00am
8-K
EX-99.2
v39hfg
15 May 19
Results of Operations and Financial Condition
9:00am
8-K
EX-99.1
ahchy2edifli
9 May 19
Other Events
8:10am
DEF 14A
uwe12qjaxjztsg
27 Mar 19
Definitive proxy
4:01pm
8-K
EX-1.1
871 waxhy7b
20 Mar 19
Public Offering of Common Stock
9:42pm
424B5
l0aac6scfm nm5nx
20 Mar 19
Prospectus supplement for primary offering
5:13pm
424B5
y2xeja0l60zrfptcmin
18 Mar 19
Prospectus supplement for primary offering
4:25pm
8-K
EX-99.1
way6y866wgetmu
18 Mar 19
Positive End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA); Phase 3 program of RTB101 expected to initiate in 2Q19
4:02pm
8-K
EX-99.2
o6vj4
18 Mar 19
Regulation FD Disclosure
7:21am
8-K
EX-99.1
ovoilmox24 t6qjwq
18 Mar 19
Regulation FD Disclosure
7:21am
8-K
EX-99.1
he3ge
7 Feb 19
Regulation FD Disclosure
8:01am
S-3
EX-1.2
x2vj dng1qgbp
1 Feb 19
Shelf registration
5:31pm
S-3
EX-4.6
fknu6tt3jcv 7yjw45s
1 Feb 19
Shelf registration
5:31pm
S-3
1qjyyhm9g
1 Feb 19
Shelf registration
5:31pm
S-3
EX-4.5
p2tr1f j86uj3e
1 Feb 19
Shelf registration
5:31pm
8-K
EX-99.1
ata8m20ont gv81r
7 Jan 19
Regulation FD Disclosure
8:00am
8-K
EX-99.1
kll72s7 mngxc
13 Nov 18
Initiation of pivotal Phase 3 program of RTB101 in RTIs expected in 1H19
8:10am